115 related articles for article (PubMed ID: 17881774)
1. Modes of actions of two types of anti-neoplastic drugs, dacarbazine and ACNU, to induce apoptosis.
Sanada M; Hidaka M; Takagi Y; Takano TY; Nakatsu Y; Tsuzuki T; Sekiguchi M
Carcinogenesis; 2007 Dec; 28(12):2657-63. PubMed ID: 17881774
[TBL] [Abstract][Full Text] [Related]
2. Different initial steps of apoptosis induced by two types of antineoplastic drugs.
Takagi Y; Hidaka M; Sanada M; Yoshida H; Sekiguchi M
Biochem Pharmacol; 2008 Aug; 76(3):303-11. PubMed ID: 18573489
[TBL] [Abstract][Full Text] [Related]
3. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
Felsberg J; Thon N; Eigenbrod S; Hentschel B; Sabel MC; Westphal M; Schackert G; Kreth FW; Pietsch T; Löffler M; Weller M; Reifenberger G; Tonn JC;
Int J Cancer; 2011 Aug; 129(3):659-70. PubMed ID: 21425258
[TBL] [Abstract][Full Text] [Related]
4. The effect of o6-methylguanine-DNA methyltransferase (MGMT) and mismatch repair gene (hMLH1) status on the sensitivity to alkylating agent 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea(ACNU) in gallbladder carcinoma cells.
Sato K; Kitajima Y; Koga Y; Miyazaki K
Anticancer Res; 2005; 25(6B):4021-8. PubMed ID: 16309194
[TBL] [Abstract][Full Text] [Related]
5. Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.
Stark AM; Doukas A; Hugo HH; Hedderich J; Hattermann K; Maximilian Mehdorn H; Held-Feindt J
Neurol Res; 2015 Feb; 37(2):95-105. PubMed ID: 24995467
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis and mutation in the murine small intestine: loss of Mlh1- and Pms2-dependent apoptosis leads to increased mutation in vivo.
Sansom OJ; Bishop SM; Court H; Dudley S; Liskay RM; Clarke AR
DNA Repair (Amst); 2003 Sep; 2(9):1029-39. PubMed ID: 12967659
[TBL] [Abstract][Full Text] [Related]
7. Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations.
Sanada M; Takagi Y; Ito R; Sekiguchi M
DNA Repair (Amst); 2004 Apr; 3(4):413-20. PubMed ID: 15010317
[TBL] [Abstract][Full Text] [Related]
8. Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
Ganesa S; Sule A; Sundaram RK; Bindra RS
Sci Rep; 2022 Apr; 12(1):5827. PubMed ID: 35388070
[TBL] [Abstract][Full Text] [Related]
9. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
Wagner LM; McLendon RE; Yoon KJ; Weiss BD; Billups CA; Danks MK
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5418-25. PubMed ID: 17875772
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
von Bueren AO; Bacolod MD; Hagel C; Heinimann K; Fedier A; Kordes U; Pietsch T; Koster J; Grotzer MA; Friedman HS; Marra G; Kool M; Rutkowski S
Br J Cancer; 2012 Oct; 107(8):1399-408. PubMed ID: 22976800
[TBL] [Abstract][Full Text] [Related]
11. Nuclear import of human MLH1, PMS2, and MutLalpha: redundancy is the key.
Leong V; Lorenowicz J; Kozij N; Guarné A
Mol Carcinog; 2009 Aug; 48(8):742-50. PubMed ID: 19148896
[TBL] [Abstract][Full Text] [Related]
12. Truncation of the C-terminus of human MLH1 blocks intracellular stabilization of PMS2 and disrupts DNA mismatch repair.
Mohd AB; Palama B; Nelson SE; Tomer G; Nguyen M; Huo X; Buermeyer AB
DNA Repair (Amst); 2006 Mar; 5(3):347-61. PubMed ID: 16338176
[TBL] [Abstract][Full Text] [Related]
13. Nuclear translocation of mismatch repair proteins MSH2 and MSH6 as a response of cells to alkylating agents.
Christmann M; Kaina B
J Biol Chem; 2000 Nov; 275(46):36256-62. PubMed ID: 10954713
[TBL] [Abstract][Full Text] [Related]
14. Expression of DNA repair proteins MSH2, MLH1 and MGMT in human benign and malignant thyroid lesions: an immunohistochemical study.
Giaginis C; Michailidi C; Stolakis V; Alexandrou P; Tsourouflis G; Klijanienko J; Delladetsima I; Theocharis S
Med Sci Monit; 2011 Feb; 17(3):BR81-90. PubMed ID: 21358597
[TBL] [Abstract][Full Text] [Related]
15. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer.
Norris AM; Woodruff RD; D'Agostino RB; Clodfelter JE; Scarpinato KD
Prostate; 2007 Feb; 67(2):214-25. PubMed ID: 17044039
[TBL] [Abstract][Full Text] [Related]
16. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.
Kaina B; Christmann M; Naumann S; Roos WP
DNA Repair (Amst); 2007 Aug; 6(8):1079-99. PubMed ID: 17485253
[TBL] [Abstract][Full Text] [Related]
17. Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma.
Shinsato Y; Furukawa T; Yunoue S; Yonezawa H; Minami K; Nishizawa Y; Ikeda R; Kawahara K; Yamamoto M; Hirano H; Tokimura H; Arita K
Oncotarget; 2013 Dec; 4(12):2261-70. PubMed ID: 24259277
[TBL] [Abstract][Full Text] [Related]
18. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the efficacy of temozolomide and dacarbazine melanoma treatment by DNA-repair factors in vivo and in vitro.
Boeckmann L; Thoms KM; Gutzmer R; Has C; Kunz M; Kuschal C; Laspe P; Struever D; Emmert S
Int J Clin Pharmacol Ther; 2009 Jan; 47(1):33-5. PubMed ID: 19203531
[No Abstract] [Full Text] [Related]
20. Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse.
Chen PC; Dudley S; Hagen W; Dizon D; Paxton L; Reichow D; Yoon SR; Yang K; Arnheim N; Liskay RM; Lipkin SM
Cancer Res; 2005 Oct; 65(19):8662-70. PubMed ID: 16204034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]